Recursion Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75629V1044
SecurityMX:RXRX / Recursion Pharmaceuticals, Inc.
InstitutionPrivate Advisor Group, LLC
Latest Disclosed Ownership66,839 shares
Latest Disclosed Value $ 205,197
Private Advisor Group, LLC reports 15.49% increase in ownership of RXRX / Recursion Pharmaceuticals, Inc.

On April 24, 2026 - Private Advisor Group, LLC filed a 13F-HR form disclosing ownership of 66,839 shares of Recursion Pharmaceuticals, Inc. (MX:RXRX) valued at $205,197 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 57,872 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of 15.49% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 66,839 8,967 15.49 205 -13.14 0.0009
2026-02-17 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 57,872 4,849 9.15 237 -8.53 0.0011
2025-11-13 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 53,023 -25,908 -32.82 259 -35.34 0.0013
2025-08-11 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 78,931 34,624 78.15 399 70.51 0.0022
2025-05-05 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 44,307 12,880 40.98 234 10.38 0.0014
2025-02-03 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 31,427 16,008 103.82 212 109.90 0.0012
2024-10-22 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 15,419 3,432 28.63 102 13.48 0.0006
2024-08-05 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 11,987 11,987 90 0.0006
2024-02-06 2023-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 0 -10,326 -100.00 0 -100.00
2023-11-03 2023-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 10,326 10,326 79 0.0007
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.